CDKL5

Across TCGA pan-cancer cohorts, CDKL5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CDKL5 data layer compared with 18 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CDKL5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDKL5 expression acts as an unfavorable survival marker.

LSCC, PDAC, and LUAD are the cancer types where CDKL5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.644	0.904	.005	12	view →
PDAC	OS	Quartile	III,IV	0.320	0.707	.047	5	view →
LUAD	DFS	Median	III,IV	0.288	0.683	.020	5	view →
CCRCC	DFS	Median	III,IV	0.858	1.000	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CDKL5–LSCC (DFS)

Open the LSCC breakdown →